Abstract: The present invention relates to thermostable quick-dissolving thin films comprising a biological moiety and an excipient mix which are suitable for the formulation of biological moieties such as viral vaccines, to methods for manufacturing such thermostable quick-dissolving thin films, and to their use in therapy. The excipient mix comprises one or more water-soluble polymer(s), a sugar selected from sucrose, trehalose and a combination thereof, a metal ion, a carboxylate, and a buffering agent.

Abstract: The invention relates to products in the form of pads or films for treating bleeding wounds, said products being formed from an organic polymer material that contains at least one particulate, crystalline inorganic polyphosphate finely divided in the organic polymer material, and the polyphosphate having a solubility in deionized water at 20° C. of less than 5 g/L, particularly less than 1 g/L, and the anion of the polyphosphate on average (number average) having at least four phosphorus atoms per polyphosphate anion.

Abstract: The invention describes a buffered oral aqueous apixaban suspension comprising 0.08-0.20 w/v % micronized apixaban having a pH of 1.5-6.5 and a method for the preparation thereof.

Abstract: An object of the present disclosure is providing a hard capsule made of a hard capsule film having enteric properties that can be molded by a cold gel method. An enteric hard capsule comprises a film containing a first component and a second component, and further containing at least one component selected from the group consisting of a third component, a fourth component, and a fifth component, wherein the first component is a nonionic water-soluble cellulose compound having a viscosity value within a range of from 100 mPa·s to 100,000 mPa·s, the second component is an enteric methacrylic acid copolymer, the third component is an enteric cellulose compound, wherein the fourth component is a water-insoluble (meth)acrylic acid alkyl ester copolymer, and the fifth component is at least one kind selected from the group consisting of polyvinyl alcohol, a plasticizer, and a surfactant.

Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.

Abstract: Embodiments of the invention relate generally to electrospun fibers and, more particularly, to the controlled release of an active pharmaceutical ingredient (API) from electrospun fiber scaffolds (EFSs).

Abstract: A copolymer poly(ethylene glycol)-polyallyl mercaptan (PEG-PAM) material is used as a drug-containing coating for medical implants. In one embodiment, a mixture of multi-arm poly(ethylene glycol) (PEG), polyallyl mercaptan (PAM), a photoinitiator, organic solvent, and one or more drugs, medicaments, or pharmaceutical compounds is applied to a surface of the implant and is exposed to a polymerizing light source to form a PEG-PAM material coating that is formed in situ on the implant. The PEG-PAM coating may be used by surgeons to incorporate antibacterial drugs or the like into coatings that are applied in the operating room setting to medical devices such as orthopedic implants. The type of drug and dosing can be customized during the coating operation and tailored to the patient's needs. PEG-PAM may also be applied as a coating on or within tissue or an injectable gel.

Abstract: A pH-responsive hydrogel, which is synthesized by using mixed pectin and sucralfate treated with a small amount of acid to form a pH-responsive hydrogel. The pH-responsive hydrogel can form a temporary coating on the surface of the gastrointestinal tract to reduce excessive nutrient absorption, and exhibits excellent barrier properties and mucosal adhesion effects, which are useful for reducing blood sugar rise and weight gain, the liver fat accumulation, body fat accumulation and blood low-density lipoprotein that have a significant effect. In addition, the technical principles disclosed in the pH-responsive hydrogel should be applied to other polymer materials to manufacture different pH-responsive hydrogels.

Abstract: The present disclosure is directed to radiation triggered liposomes and their use in delivery and release of pharmaceutical drugs upon exposure to ionizing radiation. In one embodiment liposomes are provided that comprise cholesterol and sphingolipids modified to comprise reactive groups that are activated by ionizing radiation to form crosslinks with other lipids of the liposome causing the release of the liposomal contents.

Abstract: A formulation contains at least one natural Cannabis material, at least one solvent, and at least one stabilizer. The formulation is a liquid suspension having a particle size (D90) of below 500 nm. The formulation can be used in the treatment of a disease.

Abstract: The disclosure relates to porous and non-porous silica capsules (capsules in capsule or core-shell capsules), porous microspheres, as well as their direct phase emulsification process without surfactant and their use, wherein the particles comprise a liposoluble active/payload.

Abstract: Solid oral dosage forms containing 325 mg of acetaminophen and 97.5 mg of ibuprofen or 500 mg of acetaminophen and 150 mg of ibuprofen, wherein the ibuprofen has a [D50] between 1 and 9 ?m, are described.

Abstract: A process can be used for preparing a polymer coated hard-shell capsule, filled with a fill containing a biologically active ingredient. The hard-shell capsule contains a body and a cap, and in a closed state, the cap overlaps the body in a pre-locked state or a final-locked state. The material of the body and cap contains an ethyl-, methyl-, or propyl-ether of cellulose, starch, or pullulan. The hard-shell capsule is coated with a coating layer, containing one or more anionic cellulose(s), ethyl cellulose, and/or one or more starches comprising at least 35% by weight of amylose, where the coating layer is present in an amount of about 1 to 5.8 mg/cm2. The process involves providing the polymer-coated hard-shell capsule in the pre-locked state to a capsule-filling machine, separating the body and the cap, filling the body with the fill, and rejoining the body and the cap in the final-locked state.

Abstract: This invention provides a way for drugs to kill a wide variety of otherwise invulnerable arthropods, which are protected by an unwettable plastron shield that encoats their bodies, by providing the drug with a means of egress through this plastron. Also, many arthropod-related diseases are caused by a combination of underlying factors, not just the mite. This invention allows for the concomitant use of other, non-mite-related, lipophilic drugs. This “combo” drug approach potentially allows for the treatment of the all of factors causing the disease at the same time.

Abstract: The invention relates to the use, as a herbicide, of at least one compound chosen from the compounds of general formula (I) and organic or inorganic salts thereof and isomers thereof. The invention also relates to a phytotoxic composition and to a method for controlling the development of and/or treating undesirable plants on the surface of a target zone.

Abstract: A process is provided for encapsulating glutathione (GSH), 3,3?-diindolylmethane (DIM), coenzyme-Q10 (CoQ10), and other hydrophobic antioxidant compounds by using whey proteins which may be polymerized in a particular manner. Further, compositions comprising polymerized whey protein (PWP) encapsulated glutathione, polymerized whey protein (PWP) encapsulated CoQ10, and polymerized whey protein (PWP) encapsulated DIM are provided.

Abstract: A pharmaceutical composition and method for treating opioid overdose, opioid dependency, and xylazine exposure is disclosed, utilizing an aqueous solution of sodium chloride. This solution contains active ingredients such as naloxone and yohimbine in specific concentrations, with naloxone targeting opioid overdose and yohimbine aimed at counteracting xylazine effects. In various embodiments, additional components like tolazoline and different buffers can be included. The disclosure introduces a unique delivery system that features a capsule with a vibrating mesh atomizer for efficient administration. Specifically, for yohimbine, a dual-reservoir capsule design facilitates controlled mixing with diluents or buffers. The administration of this pharmaceutical composition can be achieved through multiple methods, including intramuscular, intravenous, and atomized routes. The atomizing device incorporates a removable cap and a resilient air bladder, ensuring effective drug delivery.

Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water, a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.

Abstract: The invention relates to Bis-thiol compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating, managing or lessening the severity of pulmonary infections in a subject, the method comprising administering to the subject a bismuth-thiol (BT) composition that comprises at least one BT compound.

Abstract: In the present invention, the whole preparation process of the sustained-release microparticles is at normal or low temperature, which is highly advantageous for the preparation of a polymer-based composition from a high-temperature-sensitive drug, particularly a protein, nucleic acid and peptide drug, and the bioactivity of the active substance can be maintained to the greatest extent throughout the process compared to the disclosed technology; at the same time, the prepared sustained-release microparticles have an excellent sustained-release effect close to zero order, and the drug concentration is stabilized during the release, which overcomes the defects that the microparticles obtained by the conventional S/O/W process of pre-preparing the drug microparticles have no drug release in the earlier stage and a rapid release of the drug in the later stage; and in addition, the sustained-release microparticles have higher drug loading rate and drug encapsulation rate.